Huge names like Lupin Ltd. Mahindra & Mahindra Monetary Companies Ltd. and Brigade Enterprises Ltd. amongst others are set to see motion going into commerce on Friday.
-
Lupin: The corporate has acquired USFDA approval for Raltegravir tablets. Raltegravir tablets are used to deal with HIV-1 an infection in adults. US market dimension estimated at $34 million (IQVIA MAT March 2025.
-
Mahindra and Mahindra Monetary Companies: The corporate has authorized the rights subject of Rs 194 per share for an mixture quantity of as much as Rs 2,996 crore. The report date for figuring out the eligible shareholders is Could 14. The rights subject will open for subscription on Could 22 and shut on June 6.
-
Brigade Enterprises: The corporate will develop a premium industrial undertaking with a gross growth of over Rs 2,000 crore in Bengaluru.
-
Tata Motors: The Nationwide Firm Legislation Tribunal has authorized the merger of Tata Motors Finance with the corporate, making Tata Motors Finance not a step-down subsidiary.
-
Infosys: In-tech Automotive Engineering voluntarily dissolves its Mexican subsidiary.
-
Bharat Petroleum Corp: The corporate has been awarded contracts for the event of 100 MW wind farm tasks — 50 MW every within the states of Madhya Pradesh and Maharashtra. This initiative is a significant step in BPCL’s technique to transition to renewable power and cut back reliance on imported fossil-based energy.
-
Oil & Pure Gasoline Corp: The corporate’s contract with BP because the technical service supplier for the Mumbai Excessive subject stays in impact, as clarified in studies confirming that the Mumbai Excessive tender has not been canceled regardless of uncertainties relating to the BP partnership.
-
Gensol Engineering: SEBI has knowledgeable the corporate concerning the appointment of a Forensic Accountant and Investigator to hold out a forensic audit of its monetary statements for the monetary years ended March 31, 2022, 2023, 2024, and 2025 (evaluate interval).
-
Birla Corp: The corporate has authorized capital expenditure for capability enlargement, together with the institution of a 3.70 MTPA manufacturing unit in Madhya Pradesh and the event of two Greenfield Grinding Items in Uttar Pradesh, with a mixed capability of three.40 MTPA.
Earnings Publish Market Hours
L&T Q4FY25 Highlights (Consolidated, YoY)
-
Income up 10.9% to Rs 74,392.28 crore versus Rs 67,078.68 crore (Bloomberg estimate: 76,298 crore).
-
Ebitda up 13.4% to Rs 8,202.63 crore versus Rs 7,234.18 crore (Bloomberg estimate: 8301.3 crore).
-
Margin at 11% versus 10.8% (Bloomberg estimate: 10.9%).
-
Web Revenue up 25.0% to Rs 5,497.26 crore versus Rs 4,396.12 crore (Bloomberg estimate: 4,545 crore).
REC Q4FY25 Highlights (Consolidated, YoY)
-
Whole Earnings up 20.8% to Rs 15,348 crore versus Rs 12,707 crore.
-
NII up 37.58% at Rs 5879 crore versus Rs 4273 crore.
-
GNPA at 1.35% versus 1.95% (QoQ).
-
NNPA at 0.38% versus 0.74% (QoQ).
-
Web revenue up 5.7% to Rs 4,310 crore versus Rs 4,079 crore.
-
NIMs have improved barely, positively for us.
-
Anticipate to proceed runrate of 12% progress in FY25.
EPL Q4FY25 Highlights (Consolidated, YoY)
-
Income up 7.4% to Rs 1,105 crore, in comparison with Rs 1,029 crore.
-
Ebitda up 19.4% to Rs 228 crore in comparison with Rs 191 crore.
-
Margin at 20.6%, in comparison with the earlier 18.5%.
-
Web Revenue at Rs 114 crore, in comparison with Rs 22.3 crore.
-
One-time Loss: Considerably decreased to Rs 3.6 crore, in comparison with Rs 60.5 crore within the earlier 12 months.
Biocon Q4FY25 Outcomes Highlights (Consolidated, YoY)
-
Income up 12.8% to Rs 4,417 crore versus Rs 3,917 crore (Bloomberg estimate: Rs 4,133 crore).
-
Ebitda up 17.7% to Rs 1,078 crore versus Rs 916 crore (Bloomberg estimate: Rs 933 crore).
-
Margin at 24.4% versus 23.4% (Bloomberg estimate: 22.6%).
-
Web revenue up 154.8% to Rs 344 crore versus Rs 135 crore (Bloomberg estimate: Rs 197.9 crore).
-
Generics enterprise delivered 46% YoY and a sturdy 53% sequential progress in This autumn, concluding FY25 with an total 8% progress over the earlier 12 months.
-
Biocon Biologics continued its progress momentum in This autumn, a sturdy 9% year-on-year income pushed by vital market share features within the U.S. and key tender wins in Rising Markets.
Titan Q4FY25 Outcomes Highlights (Consolidated, YoY)
-
Income up 19.4% to Rs 14,916 crore versus Rs 12,494 crore (Bloomberg estimate: Rs 13,693 crore).
-
Ebitda up 29.1% to Rs 1,537 crore versus Rs 1,191 crore (Bloomberg estimate: Rs 1,353.8 crore).
-
Margin at 10.3% versus 9.5% (Bloomberg estimate: 9.9%).
-
Web Revenue up 13% to Rs 871 crore versus Rs 771 crore (Bloomberg estimate: Rs 855 crore).
Kalyan Jewellers Q4FY25 Highlights (Consolidated, YoY)
-
Income up 36.6% to Rs 6,181 crore versus Rs 4,525 crore. (Bloomberg estimate: Rs 6,167.7 crore).
-
Ebitda up 34.8% to Rs 399 crore versus Rs 296 crore.
-
Margin at 6.4% versus 6.5%.
-
Web revenue up 36.2% to Rs 188 crore versus Rs 138 crore. (Bloomberg estimate: Rs 185.8 crore)
Jindal Stainless Q4FY25 Highlights (Consolidated, YoY)
-
Income up 8% to Rs 10,198 crore versus Rs 9,454 crore. (Bloomberg estimate: 10,568 crore).
-
Ebitda up 2.5% to Rs 1,061 crore versus Rs 1,035 crore. (Bloomberg estimate: 1,091.6 crore).
-
Margin at 10.4% versus 11%. (Bloomberg estimate: 10.3%).
-
Web revenue up 18% to Rs 591 crore versus Rs 501 crore. (Bloomberg estimate: 526 crore).
Pidilite Industries Q4FY25 Highlights (Consolidated, YoY)
-
Income up 8.2% to Rs 3,141 crore versus Rs 2,902 crore.
-
Ebitda up 9.6% to Rs 632.5 crore versus Rs 577 crore.
-
Ebitda margin at 20.1% versus 19.8%.
-
Web revenue up 40.5% to Rs 422.3 crore versus Rs 300.6 crore.
IIFL Finance Ltd. Q4FY25 Highlights (Standalone, YoY)
-
Whole Earnings down 18.4% to Rs 1,140.68 crore versus Rs 1,398.12 crore.
-
NII down 29.76% at Rs 517 crore versus Rs 736 crore.
-
GNPA at 2.23% versus 2.42% (QoQ).
-
NNPA at 1.05% versus 1.01% (QoQ).
-
Web revenue down 76.9% to Rs 38.42 crore versus Rs 165.03 crore.
Muthoot Microfin Q4FY25 Highlights (YoY)
-
Whole Earnings down 13.8% at Rs 556 crore versus Rs 645 crore (YoY).
-
Web Lack of Rs 401 crore versus revenue of Rs 120 crore (YoY).
-
GNPA at 4.84% versus 3.03% (QoQ).
-
NNPA at 1.34% versus 1.27% (QoQ).
Dilip Buildcon Q4FY25 (Consolidated, YoY)
-
Income down 8% at Rs 3096 crore versus Rs 3365 crore.
-
Ebitda up 100.91% at Rs 661 crore versus Rs 329 crore.
-
Ebitda margin up 1157 bps at 21.35% versus 9.77%.
-
Web revenue up 10352.83% at Rs 277 crore versus Rs 2.65 crore.
Britannia Industries Q4FY25 Highlights (Consolidated, YoY)
-
Income up 9% to Rs 4,432.19 crore versus Rs 4,069.36 crore (Bloomberg estimate: Rs 4,388.1 crore)
-
Web Revenue up 4% to Rs 560 crore versus Rs 538.28 crore (Bloomberg estimate: Rs 513.1 crore)
-
Ebitda up 2.3% to Rs 805.17 crore versus Rs 787.45 crore (Bloomberg estimate: Rs 752.2 crore)
-
Margin at 18.2% versus 19.4% (Bloomberg estimate: 17.1%)
Aarti Industries Q4FY25 Highlights (Consolidated, YoY)
-
Income up 9.9% to Rs 1,949 crore versus Rs 1,773 crore (Bloomberg estimate: Rs 1,908.6 crore).
-
Ebitda down 5.3% to Rs 268 crore versus Rs 283 crore (Bloomberg estimate: Rs 252.5 crore).
-
Margin at 13.8% versus 16% (Bloomberg estimate: 13.2%).
-
Web Revenue down 27.3% to Rs 96 crore versus Rs 132 crore (Bloomberg estimate: Rs 66.8 crore).
Zee Leisure Q4FY25 Highlights (Consolidated, YoY)
-
Income up 0.7% to Rs 2,184 crore versus Rs 2,169.6 crore.
-
Ebitda up 41.6% at Rs 298 crore versus Rs 210 crore.
-
Margin at 13.6% versus 9.9%.
-
Web Revenue Rs 188.4 crore versus Rs 13.4 crore.
R Methods Q4FY25 Outcomes Highlights (Consolidated, YoY)
-
Income up 6.19% at Rs 442.4 crore versus Rs 416.6 crore.
-
Web revenue up 40.51% at Rs 38.5 crore versus Rs 27.4 crore.
-
Ebitda up 32.33% at Rs 70.4 crore versus Rs 53.2 crore.
-
Margin at 15.91% versus 12.77%.
This autumn Earnings – Rain Industries (Consolidated, YoY)
-
Income up 2.7% at Rs 3,768 crore versus Rs 3,670 crore.
-
Ebitda up 11.2% at Rs 380 crore verus Rs 342 crore.
-
Margin at 10% vs 9.3%.
-
Web lack of Rs 138 crore versus lack of Rs 146 crore.
Superb Organics Q4FY25 Outcomes Highlights (Consolidated, YoY)
-
Income up 11% at Rs 607 crore versus Rs 547 crore.
-
Ebitda down 16.7% at Rs 119 crore versus Rs 144 crore.
-
Margin at 19.7% versus 26.2%.
-
Web revenue down 15% at Rs 97 crore versus Rs 114 crore.
Union Financial institution of India Q4FY25 Highlights (Standalone, YoY)
-
Web revenue up 50.6% at Rs 4,985 crore versus Rs 3,310 crore.
-
Web Curiosity Earnings up 1% at 9,514 crore versus Rs 9,437 crore.
-
Gross NPA at 3.6% versus 3.85% (QoQ).
-
Web NPA at 0.63% versus 0.82% (QoQ).
-
Working revenue up 17.9% at Rs 7,700 crore versus Rs 6,533 crore.
-
Provisions up 22.6% at Rs 1,544 crore versus Rs 1,260 crore.
-
Provisions down 3.4% at Rs 1,544 crore versus Rs 1,599 crore.
Earnings In Focus
ABB India, Alkyl Amines Chemical substances, Aditya Imaginative and prescient, Financial institution of India, Birla Company, Cera Sanitaryware, Cholamandalam Monetary Holdings, Dr Reddys Laboratories, Eveready Industries India, Nice Japanese Delivery Firm, Grindwell Norton, India Shelter Finance Company, Mind Design Area, Jupiter Life Line Hospitals, Kirloskar Ferrous Industries, Ok.P.R. Mill, Lloyds Enterprises, Manappuram Finance, C.E. Data Methods, Motherson Sumi Wiring India, Navin Fluorine Worldwide, Novartis India, PTC India Monetary Companies, Relaxo Footwears, Reliance Energy, Shakti Pumps India, Shyam Metalics and Power, Swiggy, Thermax.
. Learn extra on Markets by Newsstate24 Revenue.
